SOPHiA GENETICS SA Files 20-F Annual Report for Fiscal Year 2023

Ticker: SOPH · Form: 20-F · Filed: 2024-03-05T00:00:00.000Z

Sentiment: neutral

Topics: SOPHiA GENETICS, 20-F Filing, Annual Report, 2023 Fiscal Year, Swiss Company

TL;DR

<b>SOPHiA GENETICS SA has submitted its 2023 annual report on Form 20-F, detailing its financial performance and corporate information.</b>

AI Summary

SOPHiA GENETICS SA (SOPH) filed a Foreign Annual Report (20-F) with the SEC on March 5, 2024. SOPHiA GENETICS SA filed its 20-F annual report on March 5, 2024, for the fiscal year ending December 31, 2023. The company is incorporated in V8 and its principal executive offices are located in Rolle, Switzerland. The filing covers the period from January 1, 2023, to December 31, 2023. Financial data for the years 2021, 2022, and 2023 are included in the filing. The SIC code for SOPHiA GENETICS SA is 2836, related to Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking SOPHiA GENETICS SA, this filing contains several important signals. This filing provides a comprehensive overview of SOPHiA GENETICS SA's financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. As a foreign private issuer, the 20-F filing is the primary annual disclosure document, offering insights into the company's business, risk factors, and financial statements under SEC regulations.

Risk Assessment

Risk Level: medium — SOPHiA GENETICS SA shows moderate risk based on this filing. The company's financial performance and growth trajectory are not detailed in this specific filing excerpt, making it difficult to assess its current financial health or future potential.

Analyst Insight

Investors should review the full 20-F filing to analyze SOPHiA GENETICS SA's financial statements, revenue growth, profitability, and management's discussion of results.

Key Numbers

Key Players & Entities

FAQ

When did SOPHiA GENETICS SA file this 20-F?

SOPHiA GENETICS SA filed this Foreign Annual Report (20-F) with the SEC on March 5, 2024.

What is a 20-F filing?

A 20-F is a annual report for foreign private issuers, equivalent to a 10-K but following international reporting standards. This particular 20-F was filed by SOPHiA GENETICS SA (SOPH).

Where can I read the original 20-F filing from SOPHiA GENETICS SA?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SOPHiA GENETICS SA.

What are the key takeaways from SOPHiA GENETICS SA's 20-F?

SOPHiA GENETICS SA filed this 20-F on March 5, 2024. Key takeaways: SOPHiA GENETICS SA filed its 20-F annual report on March 5, 2024, for the fiscal year ending December 31, 2023.. The company is incorporated in V8 and its principal executive offices are located in Rolle, Switzerland.. The filing covers the period from January 1, 2023, to December 31, 2023..

Is SOPHiA GENETICS SA a risky investment based on this filing?

Based on this 20-F, SOPHiA GENETICS SA presents a moderate-risk profile. The company's financial performance and growth trajectory are not detailed in this specific filing excerpt, making it difficult to assess its current financial health or future potential.

What should investors do after reading SOPHiA GENETICS SA's 20-F?

Investors should review the full 20-F filing to analyze SOPHiA GENETICS SA's financial statements, revenue growth, profitability, and management's discussion of results. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,396 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-03-05 07:02:28

Filing Documents

Key Information

Item 3. Key Information 4 D. Risk Factors 4

Information on the Company

Item 4. Information on the Company 48 A. History and Development of the Company 48 B. Business Overview 48 C. Organizational Structure 90 D. Property, Plants and Equipment 90

Unresolved Staff Comments

Item 4A. Unresolved Staff Comments 90

Operating and Financial Review and Prospects

Item 5. Operating and Financial Review and Prospects 90 A. Operating Results 91 B. Liquidity and Capital Resources 102 C. Research and Development, Patents and Licenses 104 D. Trend Information 104 E. Critical Accounting Estimates 105

Directors, Senior Management and Employees

Item 6. Directors, Senior Management and Employees 110 A. Directors and Senior Management 110 B. Compensation 112 C. Board Practices 114 D. Employees 118 E. Share Ownership 119 F. Disclosure of a Registrant's Actions to Recover Erroneously Awarded Compensation 119

Major Shareholders and Related Party Transactions

Item 7. Major Shareholders and Related Party Transactions 119 A. Major Shareholders 120 B. Related Party Transactions 122

Financial Information

Item 8. Financial Information 122 A. Consolidated Statements and Other Financial Information 122 B. Significant Changes 123

The Offer and Listing

Item 9. The Offer and Listing 123 A. Offer and Listing Details 123 C. Markets 123

Additional Information

Item 10. Additional Information 123 B. Memorandum and Articles of Association 123 C. Material Contracts 123 D. Exchange Controls 127 E. Taxation 127 H. Documents on Display 134 J. Annual Report to Security Holders 135

Quantitative and Qualitative Disclosures About Market Risk

Item 11. Quantitative and Qualitative Disclosures About Market Risk 135 Part II 137

Defaults, Dividend Arrearages and Delinquencies

Item 13. Defaults, Dividend Arrearages and Delinquencies. 137

Material Modifications to the Rights of Security Holders and Use of Proceeds

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 137

Controls and Procedures

Item 15. Controls and Procedures 137 A. Disclosure Controls and Procedures 137 B. Management's Annual Report on Internal Control Over Financial Reporting 137 C. Attestation Report of the Registered Public Accounting Firm 138 D. Changes in Internal Control Over Financial Reporting 138

Audit Committee Financial Expert

Item 16A. Audit Committee Financial Expert 138

Code of Ethics

Item 16B. Code of Ethics 138

Principal Accountant Fees and Services

Item 16C. Principal Accountant Fees and Services 138

Exemptions from the Listing Standards for Audit Committees

Item 16D. Exemptions from the Listing Standards for Audit Committees 139

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 139

Change in Registrant's Certifying Accountant

Item 16F. Change in Registrant's Certifying Accountant 139

Corporate Governance

Item 16G. Corporate Governance 139

Mine Safety Disclosure

Item 16H. Mine Safety Disclosure 140

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 140

J . Insider Trader Policies

Item 16 J . Insider Trader Policies 140

Cybersecurity

Item 16K. Cybersecurity 140 Part III 142

Financial Statements

Item 17. Financial Statements 142

Financial Statements

Item 18. Financial Statements 142

Exhibits

Item 19. Exhibits 142 Index to Financial Statements F- 1 Table of Contents ABOUT THIS ANNUAL REPORT Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to "SOPHiA GENETICS," "SOPH," the "Company," "we," "our," "ours," "us" or similar terms refer to SOPHiA GENETICS SA and its consolidated subsidiaries. Trademarks We own various trademark registrations and applications, and unregistered trademarks, including for "SOPHiA GENETICS," "SOPHiA DDM TM ," "Alamut," "SOPHiA Trial Match," "SOPHiA Insights," "SOPHiA CDx," "SOPHiA Awareness" and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this Annual Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Presentation of Financial Information Our consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board ("IASB"). None of the consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). The terms "dollar," "USD" and "$" refer to U.S. dollars and the terms "Swiss franc" and "CHF" refer to the legal currency of Switzerland, unless otherwise indicated. We have made rounding adjustments to some of the figures included in this Annual Report. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to round

Key Information

Item 3. Key Information D. Risk Factors Our business faces significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. If any of the events or developments described below were to occur, our business, results of operations, financial condition and prospects could suffer materially and the trading price of our ordinary shares could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. We may not be successful in expanding features, applications and data modalities of our SOPHiA DDM Platform and related solutions, applications, products, and services. We may experience challenges with the acquisition, development, enhancement and deployment of technology necessary for our data analytics platform technologies. If we are unable to expand our sales and marketing capabilities, including through additional strategic relationships, in a cost-effective manner, we may not be able to grow our revenue. The coverage and reimbursement status of newly developed applications and products, such as data analytics platforms and related solutions, applications, products, and services, particularly in a new category of diagnostics and therapeutics, is uncertain. An inability to obtain or maintain adequate coverage and reimbursement could limit the commercial potential of our SOPHiA DDM Platform and related solutions, applications, products, and services. If we cannot maintain our current relationships and enter into new relationships with hospitals, reference and specialty laboratories and biopharmaceutical companies, our revenue prospects could be reduced. We are highly d

View on Read The Filing